Literature DB >> 21799527

The fourth front against cancer. The first clinical trials to test engineered viruses that attack tumour cells have yielded promising results for future cancer therapies.

Philip Hunter.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21799527      PMCID： PMC3147267          DOI： 10.1038/embor.2011.138

Source DB:  PubMed          Journal:  EMBO Rep        ISSN： 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  3 in total

1.  The global health burden of infection-associated cancers in the year 2002.

Authors:  Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

2.  Oncolytic reovirus effectively targets breast cancer stem cells.

Authors:  Paola Marcato; Cheryl A Dean; Carman A Giacomantonio; Patrick W K Lee
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

Review 3.  Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury.

Authors:  Douglas Hedley; Lesley Ogilvie; Caroline Springer
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716
  3 in total
  3 in total

Review 1.  Oncolytic viruses: emerging options for the treatment of breast cancer.

Authors:  Yogesh R Suryawanshi; Tiantian Zhang; Karim Essani
Journal:  Med Oncol       Date:  2017-02-09       Impact factor: 3.738

2.  Glucarpidase to combat toxic levels of methotrexate in patients.

Authors:  Jacalyn M Green
Journal:  Ther Clin Risk Manag       Date:  2012-11-22       Impact factor: 2.423

Review 3.  Promising oncolytic agents for metastatic breast cancer treatment.

Authors:  James J Cody; Douglas R Hurst
Journal:  Oncolytic Virother       Date:  2015-06-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.